Cover Image
市場調查報告書

尋常痤瘡 : 開發中產品分析

Acne Vulgaris - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 232807
出版日期 內容資訊 英文 201 Pages
訂單完成後即時交付
價格
Back to Top
尋常痤瘡 : 開發中產品分析 Acne Vulgaris - Pipeline Review, H2 2017
出版日期: 2017年10月10日 內容資訊: 英文 201 Pages
簡介

所謂尋常性痤瘡是指臉上及軀幹上的囊脂肪腺小胞異常,其分泌物引起發炎,造成膿皰、結痂、囊胞等,甚至疼痛。青年期、髮膠、油性化妝品、頭盔皮帶的摩擦等運動用品、皮膚阻塞是致病原因,治療方法有使用抗生素。

本報告涵括全球尋常痤瘡治療藥的開發平台,提供您目前開發平台狀況和最新趨勢,藥物簡介,主要企業及開發中的產品檢討等資訊,為您概述為以下內容。

目錄

簡介

  • 分析範圍

尋常痤瘡概要

治療藥的開發

  • 尋常痤瘡開發中產品:概要
  • 尋常痤瘡:正在開發的治療藥:各企業
  • 尋常痤瘡:正在開發的治療藥:各大學·研究機關
  • 尋常痤瘡:開發中的產品:各企業
  • 尋常痤瘡:開發中的產品:各大學·研究機關

尋常痤瘡:治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

尋常痤瘡:開發治療藥的企業

  • 3SBio Inc
  • Allergan Plc
  • Almirall SA
  • Biomar Microbial Technologies
  • BioPharmX Inc
  • Braintree Laboratories Inc
  • Brickell Biotech Inc
  • Cassiopea SpA
  • Cell Medica Ltd
  • Cellceutix Corp
  • Celtaxsys Inc
  • Common Pharma Inc
  • Cutanea Life Sciences Inc
  • Dermira Inc
  • ELORAC Inc
  • Ensol Biosciences Inc
  • Foamix Pharmaceuticals Ltd
  • Galderma SA
  • GlaxoSmithKline Plc
  • Helix BioMedix Inc
  • Hovione FarmaCiencia SA
  • Lee's Pharmaceutical Holdings Ltd
  • LEO Pharma A/S
  • Novabiotics Ltd
  • Novan Inc
  • Novartis AG
  • Paratek Pharmaceuticals Inc
  • Pfizer Inc
  • Phosphagenics Ltd
  • Photocure ASA
  • Promius Pharma LLC
  • Provectus Biopharmaceuticals Inc
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
  • Sol-Gel Technologies Ltd
  • Sun Pharma Advanced Research Company Ltd
  • Valeant Pharmaceuticals International Inc
  • Vectura Group Plc
  • Vyome Biosciences Pvt Ltd
  • XBiotech Inc

藥物簡介

暫停中的計劃

開發中止的產品

產品開發里程碑

  • 關注的新聞·新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9786IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acne Vulgaris - Pipeline Review, H2 2017, provides an overview of the Acne Vulgaris (Dermatology) pipeline landscape.

Acne vulgaris is a chronic skin disease involving blockage and inflammation of pilosebaceous follicles. Symptoms include crusting of skin bumps, cysts, papules (small red bumps), scarring of the skin and redness around the skin eruptions. Risk factors include adolescence, hair gels or oil-based cosmetics, sports equipment such as helmet straps rubbing and occluding skin. Treatment includes antibiotics.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acne Vulgaris - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Acne Vulgaris (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acne Vulgaris (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Acne Vulgaris and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 12, 20, 9, 1, 17, 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively.

Acne Vulgaris (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Acne Vulgaris (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Acne Vulgaris (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Acne Vulgaris (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Acne Vulgaris (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Acne Vulgaris (Dermatology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Acne Vulgaris (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Acne Vulgaris (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Acne Vulgaris - Overview
  • Acne Vulgaris - Therapeutics Development
  • Acne Vulgaris - Therapeutics Assessment
  • Acne Vulgaris - Companies Involved in Therapeutics Development
  • Acne Vulgaris - Drug Profiles
  • Acne Vulgaris - Dormant Projects
  • Acne Vulgaris - Discontinued Products
  • Acne Vulgaris - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Acne Vulgaris, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Acne Vulgaris - Pipeline by 3SBio Inc, H2 2017
  • Acne Vulgaris - Pipeline by Almirall SA, H2 2017
  • Acne Vulgaris - Pipeline by Biomar Microbial Technologies, H2 2017
  • Acne Vulgaris - Pipeline by BioPharmX Inc, H2 2017
  • Acne Vulgaris - Pipeline by Blueberry Therapeutics Ltd, H2 2017
  • Acne Vulgaris - Pipeline by Braintree Laboratories Inc, H2 2017
  • Acne Vulgaris - Pipeline by Brickell Biotech Inc, H2 2017
  • Acne Vulgaris - Pipeline by Cassiopea SpA, H2 2017
  • Acne Vulgaris - Pipeline by Celtaxsys Inc, H2 2017
  • Acne Vulgaris - Pipeline by Common Pharma Inc, H2 2017
  • Acne Vulgaris - Pipeline by Cutanea Life Sciences Inc, H2 2017
  • Acne Vulgaris - Pipeline by Deltanoid Pharmaceuticals Inc, H2 2017
  • Acne Vulgaris - Pipeline by Dermira Inc, H2 2017
  • Acne Vulgaris - Pipeline by Eligo Bioscience SAS, H2 2017
  • Acne Vulgaris - Pipeline by ELORAC Inc, H2 2017
  • Acne Vulgaris - Pipeline by Ensol Biosciences Inc, H2 2017
  • Acne Vulgaris - Pipeline by Foamix Pharmaceuticals Ltd, H2 2017
  • Acne Vulgaris - Pipeline by Galderma SA, H2 2017
  • Acne Vulgaris - Pipeline by Helix BioMedix Inc, H2 2017
  • Acne Vulgaris - Pipeline by Hovione FarmaCiencia SA, H2 2017
  • Acne Vulgaris - Pipeline by Innovation Pharmaceuticals Inc, H2 2017
  • Acne Vulgaris - Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2017
  • Acne Vulgaris - Pipeline by LEO Pharma A/S, H2 2017
  • Acne Vulgaris - Pipeline by Melinta Therapeutics Inc, H2 2017
  • Acne Vulgaris - Pipeline by Novabiotics Ltd, H2 2017
  • Acne Vulgaris - Pipeline by Novan Inc, H2 2017
  • Acne Vulgaris - Pipeline by Novartis AG, H2 2017
  • Acne Vulgaris - Pipeline by Paratek Pharmaceuticals Inc, H2 2017
  • Acne Vulgaris - Pipeline by Pfizer Inc, H2 2017
  • Acne Vulgaris - Pipeline by Phagelux Inc, H2 2017
  • Acne Vulgaris - Pipeline by Phosphagenics Ltd, H2 2017
  • Acne Vulgaris - Pipeline by Photocure ASA, H2 2017
  • Acne Vulgaris - Pipeline by Promius Pharma LLC, H2 2017
  • Acne Vulgaris - Pipeline by Provectus Biopharmaceuticals Inc, H2 2017
  • Acne Vulgaris - Pipeline by Realm Therapeutics Plc, H2 2017
  • Acne Vulgaris - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H2 2017
  • Acne Vulgaris - Pipeline by Sol-Gel Technologies Ltd, H2 2017
  • Acne Vulgaris - Pipeline by Sun Pharmaceutical Industries Ltd, H2 2017
  • Acne Vulgaris - Pipeline by Taro Pharmaceutical Industries Ltd, H2 2017
  • Acne Vulgaris - Pipeline by Thesan Pharmaceuticals Inc, H2 2017
  • Acne Vulgaris - Pipeline by Valeant Pharmaceuticals International Inc, H2 2017
  • Acne Vulgaris - Pipeline by Vyome Biosciences Pvt Ltd, H2 2017
  • Acne Vulgaris - Pipeline by XBiotech Inc, H2 2017
  • Acne Vulgaris - Dormant Projects, H2 2017
  • Acne Vulgaris - Dormant Projects, H2 2017 (Contd..1), H2 2017
  • Acne Vulgaris - Dormant Projects, H2 2017 (Contd..2), H2 2017
  • Acne Vulgaris - Dormant Projects, H2 2017 (Contd..3), H2 2017
  • Acne Vulgaris - Dormant Projects, H2 2017 (Contd..4), H2 2017
  • Acne Vulgaris - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Acne Vulgaris, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top